hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo]
hydrochlorothiazide
RxCUI: 2704018
What the CMS Formulary Data Shows for hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo]
Per the CMS 2026 Part D formulary file, hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] (RxNorm concept RXCUI 2704018, generic name hydrochlorothiazide) appears on 2 distinct formulary files spanning 4 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.
Real-world access to hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,902,174 Part D beneficiaries filled hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] in 2023, with total plan-and-beneficiary spending of $98,660,150 and an average per-beneficiary annual cost of $20.13. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 4
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 4,902,174
- Total spending
- $98,660,150
- Avg per beneficiary
- $20.13
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo]
4 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| NaviCare (HMO D-SNP) | FALLON COMMUNITY HEALTH PLAN | T1 | Yes | $0 | MA |
| Fallon Medicare Plus Orange (HMO) | FALLON COMMUNITY HEALTH PLAN | T4 | Yes | $0 | MA |
| Fallon Medicare Plus Green (HMO) | FALLON COMMUNITY HEALTH PLAN | T4 | Yes | $56.40 | MA |
| Fallon Medicare Plus Blue (HMO) | FALLON COMMUNITY HEALTH PLAN | T4 | Yes | $72.10 | MA |
Frequently Asked Questions
Is hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] covered by Medicare Part D?
Yes, hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] is covered by 4 Medicare Part D plans (0.1% of all Part D formularies).
What tier is hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] on Medicare Part D plans?
hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.
Does hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] require prior authorization?
100% of Part D formularies require prior authorization for hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo]?
In 2023, total Medicare Part D spending on hydrochlorothiazide 800 MG Powder for Oral Suspension [Inzirqo] was $98,660,150, covering 4,902,174 beneficiaries. The average spend per beneficiary was $20.13.
Read our methodology - how this data is sourced, computed, and verified.